AMENDMENTS

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-40 (canceled).

41. (currently amended) A method for reducing cell or tissue death associated with a non-cardiovascular tissue ischemic condition in a mammalian subject, comprising administering to the subject an effective amount of a gamma-tocopherol enriched tocopherol composition comprising at least 50% gamma-tocopherol, and by said administering, reducing tissue damage related to said non-cardiovascular tissue ischemic condition.

42. (currently amended) A method for reducing cell or tissue death associated with a non-cardiovascular tissue ischemic condition in a mammalian subject, comprising administering to the subject an effective amount of a ~~gamma-tocopherol metabolite enriched composition comprising a natural~~ naturally occurring metabolite of gamma-tocopherol, and by said administering, reducing tissue damage related to said non-cardiovascular tissue ischemic condition.

43. (canceled)

44. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 60% gamma-tocopherol.

45. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 65% gamma-tocopherol.

46. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 70% gamma-tocopherol.

47. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 75% gamma-tocopherol.

48. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 80% gamma-tocopherol.

49. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 85% gamma-tocopherol.

50. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 90% gamma-tocopherol.

51. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 95% gamma-tocopherol.

52. (original) The method of claim 41 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 98% gamma-tocopherol.

53. (currently amended) The method of claim 42 wherein said naturally occurring metabolite of gamma-tocopherol ~~metabolite enriched composition~~ comprises at least 80% gamma-tocopherol metabolite.

54. (currently amended) The method of claim 42 wherein said naturally occurring metabolite of gamma-tocopherol ~~metabolite enriched composition~~ comprises at least 85% gamma-tocopherol metabolite.

55. (currently amended) The method of claim 42 wherein said naturally occurring metabolite of gamma-tocopherol ~~metabolite enriched composition~~ comprises at least 90% gamma-tocopherol metabolite.

56. (currently amended) The method of claim 42 wherein said naturally occurring metabolite of gamma-tocopherol ~~metabolite enriched composition~~ comprises at least 95% gamma-tocopherol metabolite.

57. (currently amended) The method of claim 42 wherein said naturally occurring metabolite of gamma-tocopherol ~~metabolite enriched composition~~ comprises at least 98% gamma-tocopherol metabolite.

58. (original) The method of claim 41 wherein said composition is a nutritional composition.

59. (original) The method of claim 41 wherein said composition is a pharmaceutical composition.

60. (original) The method of claim 41 wherein said composition is administered orally.

61. (original) The method of claim 41 wherein said composition is administered parenterally.

62. (original) The method of claim 41 wherein said composition comprises gamma-tocopherol in a range of about 1 to about 1000 mg per kg body weight of said mammalian subject.

63. (original) The method of claim 41 wherein said composition comprises gamma-tocopherol in a range of about 1 to about 50 mg per kg body weight of said mammalian subject.

64. (original) The method of claim 41 wherein said composition comprises gamma-tocopherol in a range of about 10 to about 100 mg per kg body weight of said mammalian subject.

Claims 65-97 (canceled)

98. (currently amended) A method for reducing cell or tissue death associated with a non-cardiovascular tissue ischemic condition in a mammalian subject, comprising administering to the subject an effective amount of ~~The method of claim 42 wherein said gamma-tocopherol metabolite is~~ 2,7,8-trimethyl-2-(β-carboxy-ethyl)-6-hydroxy chroman (gamma-CEHC), and by said administering, reducing tissue damage related to said non-cardiovascular tissue ischemic condition.

99. (new) The method of claim 41, wherein said gamma-tocopherol enriched tocopherol composition comprises less than 20% alpha-tocopherol.

100. (new) The method of claim 44, wherein said gamma-tocopherol enriched tocopherol composition comprises less than 20% alpha-tocopherol.

101. (new) The method of claim 45, wherein said gamma-tocopherol enriched tocopherol composition comprises less than 20% alpha-tocopherol.

102. (new) The method of claim 46, wherein said gamma-tocopherol enriched tocopherol composition comprises less than 20% alpha-tocopherol.

103. (new) The method of claim 47, wherein said gamma-tocopherol enriched tocopherol composition comprises less than 20% alpha-tocopherol.

104. (new) The method of claim 48, wherein said gamma-tocopherol enriched tocopherol composition comprises less than 20% alpha-tocopherol.